

Recall Notices Issued By Provincial Drug Testing Laboratories.

Date: 29th November, 2024.

Target Audience:

- National Regulatory Field Force of DRAP and Provincial Drug Control Departments.
- Healthcare Professionals (Physicians, Pharmacists & Nurses) & Veterinary professionals.
- General Public.

Alert Summary:

DDCP PV Lahore and Secretary PQCB Quetta has informed DRAP regarding recall of following batches of mentioned products:

S#	Product Name	Batch	Manufactured by	Test Results
		No.	Nº OF 60.	
1	Infusion Zeesol-5 1000 mL	2408207	Shazeb Pharmaceutical Industries	Substandard on the basis
	Dextrose Anhydrous 50 g/		Limited Hazara Trunk Road,	of Bacterial Endotoxin
	1000mL		👌 Sarai Gadaee, District Haripur,	
	Reg# 016611	C ^C	K.P.K Pakistan	
2	Sterile Water for Injection 5	WI-893	Fynk Pharmaceuticals 19-KM.	"Substandard" on the
	mL	NO N	G.T. Road, Kalashah Kaku,	basis of Visible
	Reg# 062671	N R	Lahore	Particulates in Injections
3	Infusion Cyanoco (Vitamin	6609	Solutional Pharma Labs	Adulterated
	B12) 100mL	0	Raiwind Road Bhobatian Chowk,	
	Cyanocobalamin 500	· · ·	Defence Road, 1-KM, towards	
	mcg/2mL	at	Kahna Lahore	
	Reg# 041241	NO.		
4	Infusion Cyanoco Super	6403	-do-	Adulterated
	100mL Cyanocobalamin			
	1000 mcg/2mL			
	Reg# 041242			
5	Syrup Desora Desloratadine	S23236	S.J. & G. Fazul Ellahie (PVT)	Ethylene Glycol above
	0.5mg/mL		Ltd., E-46, S.I.T.E., Karachi	the permissible limit
	Reg# 055192			



onuo HEGULA	ADDING OF PARKING AND ADDING A				
6	Inj. Isanex Sterile Powder of Ceftriaxone Sodium eq. to	IA-702		d" wi s to \$ erilit	
	Ceftriaxone 1g/Vial		Road, Faisalabad		
	Reg# 024657				
7	EmpLiMet XR tablet	39224	Horizon Healthcare (Pvt.) Ltd.,	Substandard on the basis	
	(Empaglifozin,Linagliptin,		Plot no. 33, sundar Industrial	of Assay	
	Metformic HCl)		estate, Lahore.		
	Reg# 121679				

Action initiated: -

The regulatory field force of DRAP and Provincial Drug Control departments have been directed to immediately conduct market surveys for detection and removal of these products from the market. All pharmacists and chemists working at distributors and pharmacies should immediately check their stocks and stop supplying these products. The remaining stocks should be quarantined, and the information of their supplier should be immediately provided to their area drug inspector to Navecto ensure the removal of falsified product.

Advice for Healthcare Professionals: -

DRAP requests increased vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by batches of mentioned products. Adverse reactions or quality problems experienced with the use of these products are to be reported to the National Pharmacovigilance Centre (NPC), DRAP using Adverse Event Reporting Form or online through this <u>link</u>. Further information of reporting problems to DRAP is available on this <u>link</u>.

Advice for Consumers / general public: -

Consumers should stop using products bearing the affected batch number(s) and shall contact to their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product, and report the incident to Drug Regulatory Authority of Pakistan/ National Pharmacovigilance Centre.



Drug Regulatory Authority of Pakistan محفوظ، موئثر اور معیاری اشیائے علاج

